We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2776
Prelude Therapeutics
PRLD
$390M
| $290K | ﹤0.01% |
9,275
+500
| +6% | +$16.2K |
|
2777
Rimini Street
RMNI
$471M
| $290K | ﹤0.01% |
30,100
+4,931
| +20% | +$42.8K |
|
|
TECX
2778
Tectonic Therapeutic
TECX
$606M
| $290K | ﹤0.01% |
4,329
+168
| +4% | +$13.8K |
|
2779
Mistras Group
MG
$512M
| $289K | ﹤0.01% |
28,414
+872
| +3% | +$8.61K |
|
|
VIRX
2780
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $289K | ﹤0.01% |
35,976
+5,894
| +20% | +$58.1K |
|
2781
Escalade
ESCA
$311M
| $288K | ﹤0.01% |
15,223
+233
| +2% | +$5.16K |
|
|
PVBC
2782
DELISTED
Provident Bancorp
PVBC
| $288K | ﹤0.01% |
17,963
+442
| +3% | +$7.13K |
|
|
ZY
2783
DELISTED
Zymergen Inc. Common Stock
ZY
| $288K | ﹤0.01% |
21,880
+850
| +4% | +$18K |
|
|
PARAA
2784
DELISTED
Paramount Global Class A
PARAA
| $286K | ﹤0.01% |
6,791
+1,398
| +26% | +$62.5K |
|
2785
Kodak
KODK
$983M
| $285K | ﹤0.01% |
41,908
+1,621
| +4% | +$11.8K |
|
2786
908 Devices
MASS
$364M
| $285K | ﹤0.01% |
+8,778
| New | +$298K |
|
2787
Preformed Line Products
PLPC
$2.28B
| $285K | ﹤0.01% |
4,386
-33
| -0.7% | -$2.33K |
|
2788
Byrna Technologies
BYRN
$101M
| $282K | ﹤0.01% |
+12,881
| New | +$319K |
|
2789
Identive
INVE
$61.9M
| $282K | ﹤0.01% |
14,953
+2,085
| +16% | +$35.5K |
|
|
LITS
2790
Lite Strategy Inc
LITS
$30.9M
| $281K | ﹤0.01% |
5,089
+31
| +0.6% | +$1.71K |
|
|
ADVM
2791
DELISTED
Adverum Biotechnologies
ADVM
| $280K | ﹤0.01% |
12,916
+211
| +2% | +$5.38K |
|
2792
Pure Cycle
PCYO
$261M
| $280K | ﹤0.01% |
21,021
+500
| +2% | +$7.24K |
|
|
IEA
2793
DELISTED
Infrastructure and Energy Alternatives, Inc. Common Stock
IEA
| $279K | ﹤0.01% |
24,440
+1,753
| +8% | +$21.5K |
|
2794
Puma Biotechnology
PBYI
$454M
| $278K | ﹤0.01% |
39,609
+568
| +1% | +$4.25K |
|
|
ESTE
2795
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
| $278K | ﹤0.01% |
30,168
+4
| +0% | +$37 |
|
|
LTRPA
2796
DELISTED
Liberty TripAdvisor Holdings, Inc. Series A
LTRPA
| $277K | ﹤0.01% |
89,729
+1,256
| +1% | +$4.67K |
|
2797
iBio
IBIO
$70M
| $275K | ﹤0.01% |
519
+15
| +3% | +$9.34K |
|
2798
XBiotech
XBIT
$69.2M
| $275K | ﹤0.01% |
21,245
+860
| +4% | +$13.7K |
|
|
GTYH
2799
DELISTED
GTY Technology Holdings, Inc. Common Stock
GTYH
| $273K | ﹤0.01% |
36,347
+1,084
| +3% | +$7.78K |
|
2800
Fidelity D&D Bancorp
FDBC
$317M
| $272K | ﹤0.01% |
5,400
-52
| -1% | -$2.73K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.